Wilex starts RCC Phase III

As expected, Wilex (Munich, Germany) started a placebo-controlled U.S. and EU Phase III trial (ARISER) of its Rencarex ( WX-G250) as an adjuvant to surgical kidney resection in 612 patients with clear cell renal cell carcinoma (RCC). The trial has dual primary endpoints of disease-free survival and overall survival. Wilex said it may be able to file for marketing approval on disease-free survival data before the overall survival data are available. ...